Drug Profile
BMS 986104
Alternative Names: BMS986104Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antirheumatics
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in USA (PO)
- 30 Nov 2020 BMS 986104 is still in phase I development for Rheumatoid arthritis (In volunteers) in USA (PO) (Bristol Myers Squibb pipeline, November 2020)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in USA (PO)